ST2 Cardiac Biomarkers Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)

Publication ⇒Feb-24 Delivery Time ⇒ 5-7 Business Days Report Code ⇒PBCHC368-10M-OT

License Type (Price in USD)

ST2 Cardiac Biomarkers Market – Report Overview

Pacific Business Consulting’s “ST2 Cardiac Biomarkers Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)” report offers a comprehensive understanding of ST2 Cardiac Biomarkers market, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Ten Major Markets (10MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, China, Australia, and India.

In 2022, the ST2 Cardiac Biomarkers market exceeded a valuation of over US$ xx Billion, and it is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) exceeding xx.0% from 2023 to 2030. The market is expected to potentially surpass US$ xx0 Billion by 2030.

ST2, initially discovered in 1989, gained recognition in 2002 for being expressed by cardiac cells in response to myocardial stress. It is a crucial cardiac biomarker used to assess heart failure risk and guide treatment decisions. Unlike other biomarkers, the level of ST2 in the blood changes rapidly with heart conditions, making it an effective tool for monitoring heart treatment progress. ST2 is a member of the interleukin-1 receptor family, with two isoforms: a soluble form (sST2) and a membrane-bound receptor form (ST2L).

When the myocardium undergoes stretching, the ST2 gene is upregulated, leading to an increased concentration of circulating soluble ST2. The ligand for ST2 is the cytokine interleukin-33 (IL-33), and their interaction plays a crucial role in cardioprotective signaling. However, the presence of high levels of soluble ST2 can counterbalance this signal, subjecting the heart to greater stress.

ST2 is a strong predictor and promising biomarker for both chronic and acute heart failure. The Centers for Disease Control and Prevention (CDC) identifies heart disease as the leading cause of death in the United States across various ethnicities. Clinicians increasingly rely on the ST2 biomarker to guide heart failure treatment. The recent approval of the Presage ST2 assay in Europe and the United States for prognostication in heart failure further highlights its significance.

The low biological variability of the ST2 biomarker makes it an ideal choice for monitoring heart disease. Its ability to assess the risk of heart failure and guide hospital and post-discharge care enhances its utility. The growing prevalence of heart diseases, attributed to factors like physical inactivity and an unhealthy diet, drives the ST2 biomarker market. However, challenges such as the unavailability of sufficient detection systems/products and limited awareness among clinicians may restrain market growth.

Leading players in the ST2 Cardiac Biomarkers segment, including MyBioSource, Inc., San Diego, CA. Elabscience Biotechnology, Inc., Thermo Fisher Scientific, Inc., Critical Care Diagnostics, Inc., Diagnostic Automation/Cortez Diagnostics, Inc., are expected to play a crucial role in shaping the future landscape of ST2 Cardiac Biomarkers technologies through ongoing innovation.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the ST2 Cardiac Biomarkers market. It also delves into the analysis of present and prospective market competition within the global ST2 Cardiac Biomarkers market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

  • Develop your business strategies by gaining insights into the trends that shape and drive the ST2 Cardiac Biomarkers market across the 10MM (Ten Major Markets).
  • Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 10MM ST2 Cardiac Biomarkers market.
  • Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
  • Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.
  1. Executive Summary: ST2 Cardiac Biomarkers
    • Global Market Outlook: ST2 Cardiac Biomarkers
  2. Competitive Intelligence Analysis: ST2 Cardiac Biomarkers
  3. Therapeutic Sector SWOT
  4. Technology Roadmap Analysis: ST2 Cardiac Biomarkers
  5. Market Background
    • Drivers
    • Restraints
    • Opportunity
    • Key Market Trends
    • Key Unmet Needs
  6. Key Marketed Products Profile – Major Approved Products: ST2 Cardiac Biomarkers
    • Product Profile
    • Safety and Efficacy
  7. Regulatory Landscape
  8. ST2 Cardiac Biomarkers: Ten Major Market (10MM) – Market Analysis, By Biomarker
    • ASPECT Plus Analyzer
    • Presage ST2 Assay Kit
  9. ST2 Cardiac Biomarkers: Ten Major Market (10MM) – Market Analysis, By Technology
    • Enzyme Linked Immunosorbent Assay (ELISA)
    • Immunochromatography
  10. ST2 Cardiac Biomarkers: Ten Major Market (10MM) – Market Analysis, By End User
    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Academic & Research Institutes
  11. ST2 Cardiac Biomarkers: Ten Major Market (10MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. S. ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. K. ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. Germany ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. France ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. Italy ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. Spain ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. Japan ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. China ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. Australia ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. India ST2 Cardiac Biomarkers – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Biomarker
      • By Technology
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Biomarker
      • By Technology
      • By End User
  1. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

  1. Assumptions and Acronyms Used
  2. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
  3. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, China, Australia, and India
  4. Copyrights and Disclaimer

Customize Reports As Per Your Needs

Don’t see what you’re looking for? Get a report tailored to your specific requirements. Customize your report now!

Have A Question?

We are happy to assist you.

Phone:+919599779105
Email:info@pacificbusinessconsulting.com